GTC is excited to be exhibiting at ASH for the first time and look forward to meeting people in person. Our booth # 3440 and would like you will stop by and say hello. If you would like to schedule a meeting fill out the form below We have four abstracts being presented at ASH – here is […]
Distinguishing PH-like acute lymphoblastic leukemia (ALL) from other types of ALL relies on full evaluation of the molecular abnormalities in the leukemic cells. Order GTC Hematology Molecular Profile Plus GTC Hematology Profile Plus and obtain complete evaluation of mutations in DNA of 177 genes and fusion/expression/mutations in RNA of 1408 genes. Here is an example […]
We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay leads to a worse outcome Patients with cancer who have to wait longer for treatment suffer from significant anxiety and stress Physicians and patients deserve to get the results of […]
Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible. Are you waiting 21-28 days to receive your NGS results? Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 7 days of receiving the sample. GTC tests […]
-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC) Membership in the Co-Op also makes CSI Laboratories the first to offer 177 gene liquid biopsy for hematology ALPHARETTA – CSI Laboratories, nationally renowned for its quality cancer diagnostics, goes a step forward to precision […]
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. In these patients, relapse occurs despite achievement of morphologic remission (ie, […]
Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome(MDS) Program: Oral and Poster Abstracts | Saturday, December 1, 2018: 4:00 PM Session: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics I Eltrombopag (EPAG), a thrombopoietin receptor agonist, has been shown […]
Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib Program: Oral and Poster Abstracts | Monday, December 3, 2018: 11:45 AM Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: Advances […]
Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Program: Oral and Poster Abstracts | Monday, December 3, 2018, 6:00 PM-8:00 PM Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Background: Venetoclax (VEN) is a potent and selective small molecule BCL2 inhibitor, with activity both as […]
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Saturday, December 1, 2018, 6:15 PM-8:15 PM | Hall GH (San Diego Convention Center) Background: Acute […]